CN105461686A - 制备高纯度甲磺酸达比加群酯晶型的方法 - Google Patents
制备高纯度甲磺酸达比加群酯晶型的方法 Download PDFInfo
- Publication number
- CN105461686A CN105461686A CN201410420941.0A CN201410420941A CN105461686A CN 105461686 A CN105461686 A CN 105461686A CN 201410420941 A CN201410420941 A CN 201410420941A CN 105461686 A CN105461686 A CN 105461686A
- Authority
- CN
- China
- Prior art keywords
- methylsulfonic acid
- dabigatran etcxilate
- crystal formation
- high purity
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
试验 | 投料比(摩尔比) | 反应温度 | 收率/% |
1 | 中间体②:原料C=1:0.95 | 35℃ | 86% |
2 | 中间体②:原料C=1:0.95 | 35℃ | 92% |
3 | 中间体②:原料C=1:0.95 | 35℃ | 91% |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410420941.0A CN105461686A (zh) | 2014-08-25 | 2014-08-25 | 制备高纯度甲磺酸达比加群酯晶型的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410420941.0A CN105461686A (zh) | 2014-08-25 | 2014-08-25 | 制备高纯度甲磺酸达比加群酯晶型的方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105461686A true CN105461686A (zh) | 2016-04-06 |
Family
ID=55599901
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410420941.0A Pending CN105461686A (zh) | 2014-08-25 | 2014-08-25 | 制备高纯度甲磺酸达比加群酯晶型的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105461686A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114380793A (zh) * | 2020-10-20 | 2022-04-22 | 北京澳合药物研究院有限公司 | 一种甲磺酸达比加群酯晶型i的制备方法及其应用 |
CN116621815A (zh) * | 2023-07-21 | 2023-08-22 | 成都苑东生物制药股份有限公司 | 一种甲磺酸达比加群酯的工业化制备方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1845917A (zh) * | 2003-08-29 | 2006-10-11 | 贝林格尔·英格海姆国际有限公司 | 3-[(2-{[4-(已氧基羰基氨基-亚氨基-甲基)-苯氨基]-甲基}-1-甲基-1 h-苯并咪唑-5-羰基)-吡啶-2-基-氨基]-丙酸乙酯-甲磺酸酯及其作为药物的用途 |
CN1972919A (zh) * | 2004-06-25 | 2007-05-30 | 贝林格尔·英格海姆国际有限公司 | 制备4-(苯并咪唑基甲氨基)-苯甲脒的方法 |
CN101346355A (zh) * | 2005-12-21 | 2009-01-14 | 贝林格尔·英格海姆国际有限公司 | 制备4-(苯并咪唑基甲基氨基)-苯甲脒的盐的改良方法 |
CN101346360A (zh) * | 2005-12-21 | 2009-01-14 | 贝林格尔.英格海姆国际有限公司 | 制备4-(苯并咪唑基甲基氨基)-苯甲脒及其盐的改良方法 |
WO2012027543A1 (en) * | 2010-08-25 | 2012-03-01 | Teva Pharmaceuticals Usa, Inc. | Solid state forms of dabigatran etexilate, dabigatran etexilate mesylate and processes for preparation thereof |
WO2014020555A2 (en) * | 2012-08-01 | 2014-02-06 | Alembic Pharmaceuticals Limited | An improved process for the preparation of dabigatran etexilate mesylate |
WO2014041559A2 (en) * | 2012-08-27 | 2014-03-20 | Glenmark Pharmaceuticals Limited; Glenmark Generics Limited | Process for the preparation of dabigatran etexilate and intermediates thereof |
-
2014
- 2014-08-25 CN CN201410420941.0A patent/CN105461686A/zh active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1845917A (zh) * | 2003-08-29 | 2006-10-11 | 贝林格尔·英格海姆国际有限公司 | 3-[(2-{[4-(已氧基羰基氨基-亚氨基-甲基)-苯氨基]-甲基}-1-甲基-1 h-苯并咪唑-5-羰基)-吡啶-2-基-氨基]-丙酸乙酯-甲磺酸酯及其作为药物的用途 |
CN1972919A (zh) * | 2004-06-25 | 2007-05-30 | 贝林格尔·英格海姆国际有限公司 | 制备4-(苯并咪唑基甲氨基)-苯甲脒的方法 |
CN101346355A (zh) * | 2005-12-21 | 2009-01-14 | 贝林格尔·英格海姆国际有限公司 | 制备4-(苯并咪唑基甲基氨基)-苯甲脒的盐的改良方法 |
CN101346360A (zh) * | 2005-12-21 | 2009-01-14 | 贝林格尔.英格海姆国际有限公司 | 制备4-(苯并咪唑基甲基氨基)-苯甲脒及其盐的改良方法 |
WO2012027543A1 (en) * | 2010-08-25 | 2012-03-01 | Teva Pharmaceuticals Usa, Inc. | Solid state forms of dabigatran etexilate, dabigatran etexilate mesylate and processes for preparation thereof |
WO2014020555A2 (en) * | 2012-08-01 | 2014-02-06 | Alembic Pharmaceuticals Limited | An improved process for the preparation of dabigatran etexilate mesylate |
WO2014041559A2 (en) * | 2012-08-27 | 2014-03-20 | Glenmark Pharmaceuticals Limited; Glenmark Generics Limited | Process for the preparation of dabigatran etexilate and intermediates thereof |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114380793A (zh) * | 2020-10-20 | 2022-04-22 | 北京澳合药物研究院有限公司 | 一种甲磺酸达比加群酯晶型i的制备方法及其应用 |
CN114380793B (zh) * | 2020-10-20 | 2024-02-23 | 北京澳合药物研究院有限公司 | 一种甲磺酸达比加群酯晶型i的制备方法及其应用 |
CN116621815A (zh) * | 2023-07-21 | 2023-08-22 | 成都苑东生物制药股份有限公司 | 一种甲磺酸达比加群酯的工业化制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104945302B (zh) | 苯偶酰二腙‑3‑吲哚甲醛双西弗碱的结构、制备和用途 | |
CN105399757A (zh) | 酸敏感型喜树碱-20位去甲斑蝥酸酯衍生物及其抗肿瘤应用 | |
JP2013529641A (ja) | Osi−906の多形体 | |
CN101282965A (zh) | 基于烷氧基吲哚酮的蛋白激酶抑制剂 | |
CN105461686A (zh) | 制备高纯度甲磺酸达比加群酯晶型的方法 | |
RU2648990C1 (ru) | Кристаллы лобаплатина, способы получения и применения в фармацевтике | |
CN109384768A (zh) | 玻玛西尼a晶型、b晶型、c晶型及其制备方法 | |
CN105849106B (zh) | 阿哌沙班合成中的关键中间体和杂质:阿哌沙班二醇酯 | |
CN109053593B (zh) | 1-(2,6-氯苯基)-3-(取代嘧啶-4-基)脲类化合物及其制备和应用 | |
CN111763199B (zh) | 2-噻吩基喹啉酮衍生物及其制备方法和应用 | |
CN103450119B (zh) | 一种卡巴他赛晶型w及其制备方法 | |
CN106892900A (zh) | 一种富马酸沃诺拉赞及其制备方法 | |
CN101768105A (zh) | 丁酸氯维地平的晶型 | |
CZ306732B6 (cs) | Způsob přípravy bezvodé polymorfní formy N-6 Dasatinibu | |
CN110563651A (zh) | 一种连有邻羟基苯胺的1,9-蒽二酰亚胺化合物及其制备方法和应用 | |
CN108250138A (zh) | 阿帕替尼a晶型及其制备方法和应用 | |
CN107778224B (zh) | 一种贝曲西班中间体的制备方法 | |
CN104447689B (zh) | 来那度胺的晶型及其制备方法 | |
CN103709156A (zh) | 一种达沙替尼多晶型药物及其制备方法 | |
CN103570676B (zh) | 甲磺酸伊马替尼α结晶的制备及其药物组合物 | |
CN107778295A (zh) | 迈瑞替尼化合物 | |
CN102633790B (zh) | 吡啶罗丹明噁二唑化合物及其制备方法与应用 | |
CN106661040A (zh) | 一种6‑芳基氨基吡啶酮甲酰胺化合物的结晶及其制备方法 | |
CN108250139A (zh) | 阿帕替尼b晶型及其制备方法和应用 | |
CN105294689B (zh) | 一种四取代吡唑并异喹啉化合物及其合成方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
C41 | Transfer of patent application or patent right or utility model | ||
CB02 | Change of applicant information |
Address after: Tenth Industrial Zone, Lianyungang, Jiangsu, China, 222047 Applicant after: JIANGSU HANSOH PHARMACEUTICAL GROUP Co.,Ltd. Applicant after: Lianyungang Hongchuang Pharmaceutical Co.,Ltd. Address before: Tenth Industrial Zone, Lianyungang, Jiangsu, China, 222047 Applicant before: Jiangsu best Pharmaceutical Co.,Ltd. Applicant before: Lianyungang Hongchuang Pharmaceutical Co.,Ltd. Address after: Tenth Industrial Zone, Lianyungang, Jiangsu, China, 222047 Applicant after: Jiangsu best Pharmaceutical Co.,Ltd. Applicant after: Lianyungang Hongchuang Pharmaceutical Co.,Ltd. Address before: Tenth Industrial Zone, Lianyungang, Jiangsu, China, 222047 Applicant before: JIANGSU HANSOH PHARMACEUTICAL Co.,Ltd. Applicant before: Lianyungang Hongchuang Pharmaceutical Co.,Ltd. |
|
COR | Change of bibliographic data | ||
PB01 | Publication | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160318 Address after: 222047 Lianyungang economic and Technological Development Zone, Jiangsu Applicant after: JIANGSU HANSOH PHARMACEUTICAL GROUP Co.,Ltd. Address before: Tenth Industrial Zone, Lianyungang, Jiangsu, China, 222047 Applicant before: JIANGSU HANSOH PHARMACEUTICAL GROUP Co.,Ltd. Applicant before: Lianyungang Hongchuang Pharmaceutical Co.,Ltd. |
|
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160406 |
|
RJ01 | Rejection of invention patent application after publication |